Jun Yao1, Chun-Suo Zhou1, Xiong Ma1, Bai-Qing Fu1, Li-Sheng Tao1, Miao Chen1, Ya-Ping Xu1. 1. Jun Yao, Chun-Suo Zhou, Bai-Qing Fu, Li-Sheng Tao, Ya-Ping Xu, Department of Gastroenterology, the People's Hospital Affiliated to Jiangsu University, Zhenjiang 212002, Jiangsu Province, China.
Abstract
AIM: To examine the effect of farnesoid X receptor (FXR) activation by GW4064 on endotoxin-induced hepatic inflammation in nonalcoholic fatty liver disease (NAFLD) and the underlying mechanism. METHODS: Six-week-old male C57BL/6 mice were fed a normal diet or a high-fat (HF) diet for 8 wk. HF diet-fed mice were intraperitoneally injected with GW4064 (30 mg/kg) or DMSO (vehicle) once daily for a week and then sacrificed after lipopolysaccharide (LPS, 50 μg/mouse) administration. Hepatic inflammation, levels of the macrophage marker F4/80, and apoptosis were measured at the end of the study. Additionally, the expression of proinflammatory genes involved in NAFLD (interleukin-6, interleukin-1β, interferon-γ, MCP-1) were analyzed by real-time PCR in the murine macrophage cell line RAW 264.7 cultured with or without GW4064 (2 μmol/L) before treatment with LPS. RESULTS: In patients with NAFLD, the expression of FXR was detected by immunohistochemical staining and the relation between FXR expression and NAFLD activity score (NAS) was analyzed. Activation of FXR by GW4064 alleviated hepatic inflammation induced by endotoxin in a murine NAFLD model fed an HF diet as reflected by reduced serum levels of aspartate aminotransferase and alanine aminotransferase. Apoptosis and proinflammatory cytokine levels in liver tissues were also reduced by GW4064, and GW4064 could reduce induction of proinflammatory cytokines by LPS in vitro. FXR levels were reduced in patients with non-alcoholic steatohepatitis compared with healthy controls and were negatively correlated with NAS. CONCLUSION: FXR activation attenuates LPS-induced hepatic inflammation in murine NAFLD by reducing expression of proinflammatory cytokines in macrophages.
AIM: To examine the effect of farnesoid X receptor (FXR) activation by GW4064 on endotoxin-induced hepatic inflammation in nonalcoholic fatty liver disease (NAFLD) and the underlying mechanism. METHODS: Six-week-old male C57BL/6 mice were fed a normal diet or a high-fat (HF) diet for 8 wk. HF diet-fed mice were intraperitoneally injected with GW4064 (30 mg/kg) or DMSO (vehicle) once daily for a week and then sacrificed after lipopolysaccharide (LPS, 50 μg/mouse) administration. Hepatic inflammation, levels of the macrophage marker F4/80, and apoptosis were measured at the end of the study. Additionally, the expression of proinflammatory genes involved in NAFLD (interleukin-6, interleukin-1β, interferon-γ, MCP-1) were analyzed by real-time PCR in the murine macrophage cell line RAW 264.7 cultured with or without GW4064 (2 μmol/L) before treatment with LPS. RESULTS: In patients with NAFLD, the expression of FXR was detected by immunohistochemical staining and the relation between FXR expression and NAFLD activity score (NAS) was analyzed. Activation of FXR by GW4064 alleviated hepatic inflammation induced by endotoxin in a murine NAFLD model fed an HF diet as reflected by reduced serum levels of aspartate aminotransferase and alanine aminotransferase. Apoptosis and proinflammatory cytokine levels in liver tissues were also reduced by GW4064, and GW4064 could reduce induction of proinflammatory cytokines by LPS in vitro. FXR levels were reduced in patients with non-alcoholic steatohepatitis compared with healthy controls and were negatively correlated with NAS. CONCLUSION:FXR activation attenuates LPS-induced hepatic inflammation in murine NAFLD by reducing expression of proinflammatory cytokines in macrophages.
Authors: Yanqiao Zhang; Florence Ying Lee; Gabriel Barrera; Hans Lee; Charisse Vales; Frank J Gonzalez; Timothy M Willson; Peter A Edwards Journal: Proc Natl Acad Sci U S A Date: 2006-01-12 Impact factor: 11.205
Authors: Keith R Stayrook; Kelli S Bramlett; Rajesh S Savkur; James Ficorilli; Todd Cook; Michael E Christe; Laura F Michael; Thomas P Burris Journal: Endocrinology Date: 2004-11-24 Impact factor: 4.736
Authors: Brett M McGettigan; Rachel H McMahan; Yuhuan Luo; Xiaoxin X Wang; David J Orlicky; Cara Porsche; Moshe Levi; Hugo R Rosen Journal: J Biol Chem Date: 2016-09-07 Impact factor: 5.157
Authors: Stephanie R Wesolowski; Karim C El Kasmi; Karen R Jonscher; Jacob E Friedman Journal: Nat Rev Gastroenterol Hepatol Date: 2016-10-26 Impact factor: 46.802
Authors: Detlef Schuppan; Henning Grønbæk; Konstantin Kazankov; Simon Mark Dahl Jørgensen; Karen Louise Thomsen; Holger Jon Møller; Hendrik Vilstrup; Jacob George Journal: Nat Rev Gastroenterol Hepatol Date: 2019-03 Impact factor: 46.802
Authors: Vinod S Hegade; R Alexander Speight; Rachel E Etherington; David E J Jones Journal: Therap Adv Gastroenterol Date: 2016-02-17 Impact factor: 4.409